Chemical compound
3-MeO-PCE Other names 3-MeO-PCE; Methoxieticyclidine Legal status
DE : NpSG (Industrial and scientific use only)
UK : Class B
Illegal in Sweden and Switzerland
N -Ethyl-1-(3-methoxyphenyl)cyclohexan-1-amine
CAS Number PubChem CID ChemSpider UNII CompTox Dashboard (EPA ) Formula C 15 H 23 N O Molar mass 233.355 g·mol−1 3D model (JSmol )
CCNC1(CCCCC1)C2=CC(=CC=C2)OC
InChI=1S/C15H23NO/c1-3-16-15(10-5-4-6-11-15)13-8-7-9-14(12-13)17-2/h7-9,12,16H,3-6,10-11H2,1-2H3
Key:OFGOOZLOGUNDFS-UHFFFAOYSA-N
3-Methoxyeticyclidine (3-MeO-PCE ), also known as methoxieticyclidine ,[1] is a dissociative anesthetic that is qualitatively similar to PCE and PCP [1] and has been sold online as a designer drug .[2] [3] [4]
On October 18, 2012, the Advisory Council on the Misuse of Drugs in the United Kingdom released a report about methoxetamine , saying that the "harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971) ", despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of methoxetamine should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines, including 3-MeO-PCE.[5]
This report also described the receptor binding profile of methoxetamine and three additional dissociatives 3-MeO-PCP , 4-MeO-PCP , and 3-MeO-PCE, showing them to have significant affinity for the PCP site of the NMDA receptor (NMDAR) and was later published in more detail.[6]
3-MeO-PCE has Ki values of 61 nM for the NMDAR, 743 nM for the dopamine transporter , 2097 nM for the histamine H2 receptor , 964 nM for the alpha-2A adrenergic receptor , 115 nM for the serotonin transporter , 4519 nM for the σ1 receptor , and 525 nM for the σ2 receptor .[6]
3-MeO-PCE is banned in Sweden[7] [8] and Switzerland.[9]
As per Chile's Ley de drogas, aka Ley 20000,[10] all esters and ethers of PCE are illegal. As 3-MeO-PCE is an ether of PCE, it is thus illegal.
^ a b Morris H, Wallach J (July–August 2014). "From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs". Drug Testing and Analysis . 6 (7–8): 614–32. doi :10.1002/dta.1620 . PMID 24678061 .
^ De Paoli G, Brandt SD, Wallach J, Archer RP, Pounder DJ (June 2013). "From the street to the laboratory: analytical profiles of methoxetamine, 3-methoxyeticyclidine and 3-methoxyphencyclidine and their determination in three biological matrices" . Journal of Analytical Toxicology . 37 (5): 277–83. doi :10.1093/jat/bkt023 . PMID 23552616 .
^ Wallach J, Colestock T, Cicali B, Elliott SP, Kavanagh PV, Adejare A, et al. (August 2016). "Syntheses and analytical characterizations of N-alkyl-arylcyclohexylamines" (PDF) . Drug Testing and Analysis . 8 (8): 801–15. doi :10.1002/dta.1861 . PMID 26360516 . S2CID 1599386 .
^ "3-MeO-PCE" . New Synthetic Drugs Database . Archived from the original on 2016-07-29. Retrieved 2016-08-27 .
^ "Advisory Council on the Misuse of Drugs (ACMD) Methoxetamine report, 2012" . UK Home Office . 18 October 2012.
^ a b Roth BL , Gibbons S, Arunotayanun W, Huang XP, Setola V, Treble R, Iversen L (March 2013). "The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor" . PLOS ONE . 8 (3): e59334. Bibcode :2013PLoSO...859334R . doi :10.1371/journal.pone.0059334 . PMC 3602154 . PMID 23527166 .
^ "Elva nya ämnen klassas som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten. 28 June 2018.
^ Riksdagsförvaltningen. "Förordning (1992:1554) om kontroll av narkotika" . riksdagen.se (in Swedish).
^ "Verordnung des EDI vom 30. Mai 2011 über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien (Betäubungsmittelverzeichnisverordnung, BetmVV-EDI)" (in German). Der Bundesrat.
^ "SUSTITUYE LA LEY Nº 19.366, QUE SANCIONA EL TRAFICO ILICITO DE ESTUPEFACIENTES Y SUSTANCIAS SICOTROPICAS" (in Spanish). Bibloteca Del Congreso Nacional. 22 October 2015. Retrieved 6 February 2018 .
Psychedelics (5-HT2A agonists)
Benzofurans Lyserg‐ amides Phenethyl‐ amines
2C-x 25x -NBx
25x -NB 25x -NB3OMe
25B-NB3OMe
25C-NB3OMe
25D-NB3OMe
25E-NB3OMe
25H-NB3OMe
25I-NB3OMe
25N-NB3OMe
25P-NB3OMe
25T2-NB3OMe
25T4-NB3OMe
25T7-NB3OMe
25TFM-NB3OMe
25x -NB4OMe
25B-NB4OMe
25C-NB4OMe
25D-NB4OMe
25E-NB4OMe
25H-NB4OMe
25I-NB4OMe
25N-NB4OMe
25P-NB4OMe
25T2-NB4OMe
25T4-NB4OMe
25T7-NB4OMe
25TFM-NB4OMe
25x -NBF 25x -NBMD
25B-NBMD
25C-NBMD
25D-NBMD
25E-NBMD
25F-NBMD
25H-NBMD
25I-NBMD
25P-NBMD
25T2-NBMD
25T7-NBMD
25TFM-NBMD
25x -NBOH 25x -NBOMe Atypical structures
25x -NMx
25B-NMe7BF
25B-NMe7BT
25B-NMe7Bim
25B-NMe7Box
25B-NMe7DHBF
25B-NMe7Ind
25B-NMe7Indz
25B-NMePyr
25I-NMe7DHBF
25I-NMeFur
25I-NMeTHF
25I-NMeTh
N-(2C)-fentanyl
N-(2C-B) fentanyl
N-(2C-C) fentanyl
N-(2C-D) fentanyl
N-(2C-E) fentanyl
N-(2C-G) fentanyl
N-(2C-H) fentanyl
N-(2C-I) fentanyl
N-(2C-IP) fentanyl
N-(2C-N) fentanyl
N-(2C-P) fentanyl
N-(2C-T) fentanyl
N-(2C-T-2) fentanyl
N-(2C-T-4) fentanyl
N-(2C-T-7) fentanyl
N-(2C-TFM) fentanyl
3C-x 4C-x DOx HOT-x MDxx Mescaline (subst.) TMAs
TMA
TMA-2
TMA-3
TMA-4
TMA-5
TMA-6
Others
Piperazines Tryptamines
alpha -alkyltryptaminesx -DALT x -DET x -DiPT x -DMT
4,5-DHP-DMT
2,N,N-TMT
4-AcO-DMT
4-HO-5-MeO-DMT
4,N,N-TMT
4-Propionyloxy-DMT
5,6-diBr-DMT
5-AcO-DMT
5-Bromo-DMT
5-MeO-2,N ,N -TMT
5-MeO-4,N ,N -TMT
5-MeO-α,N,N-TMT
5-MeO-DMT
5-N ,N -TMT
7,N,N-TMT
α,N,N-TMT
(Bufotenin) 5-HO-DMT
DMT
Norbaeocystin
(Psilocin) 4-HO-DMT
(Psilocybin) 4-PO-DMT
x -DPT Ibogaine-related x -MET x -MiPT Others
Others
Dissociatives (NMDAR antagonists )
Deliriants (mAChR antagonists ) Others
AMPAR Tooltip α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor KAR Tooltip Kainate receptor NMDAR Tooltip N-Methyl-D-aspartate receptor
σ1 σ2 Unsorted
Antagonists: AHD1
AZ66
Lamotrigine
Naloxone
SM-21
UMB-100
UMB-101
UMB-103
UMB-116
YZ-011
YZ-069
YZ-185